| 產(chǎn)品名稱 | 1C6 [LS77-1C6] |
|---|---|
| 商品貨號(hào) | B202249 |
| Organism | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type | hybridoma:lymphoblast B lymphocyte; somatic cell hybri |
| Product Format | frozen |
| Culture Properties | suspension |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain | Strain:? BALB/c (B cell); BALB/c (myeloma) |
| Applications | Animals were immunized with a synthetic peptide corresponding to the first 37 N-terminal amino acids of CXCR3.
Spleen cells were fused with Sp2/0 myeloma cells. |
| Storage Conditions | liquid nitrogen vapor phase |
| Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Images |  |
| Derivation | Animals were immunized with a synthetic peptide corresponding to the first 37 N-terminal amino acids of CXCR3.
Spleen cells were fused with Sp2/0 myeloma cells. The antibody recognizes surface expressed CXCR3, as judged by staining of CXCR3 transfected cells, but not untransfected cells. The antibody also stained human T cells and T cell clones that had been activated in vitro with PHA or anti-CD3. However, the anti-CXCR3 antibody did not react with neutrophils. The CXCR3 receptor is also known as the IP-10 receptor and the Mig receptor. |
| Comments | Animals were immunized with a synthetic peptide corresponding to the first 37 N-terminal amino acids of CXCR3.
Spleen cells were fused with Sp2/0 myeloma cells. The antibody recognizes surface expressed CXCR3, as judged by staining of CXCR3 transfected cells, but not untransfected cells. The antibody also stained human T cells and T cell clones that had been activated in vitro with PHA or anti-CD3. However, the anti-CXCR3 antibody did not react with neutrophils. The CXCR3 receptor is also known as the IP-10 receptor and the Mig receptor. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing | Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml.
Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml. Do not allow the cell density to exceed 1 X 10(6) cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation | Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Temperature: 37.0°C |
| Isotype | IgG1 kappa |
| Name of Depositor | LeukoSite, Inc. |
| U.S. Patent Number | |
| References | Loetscher M, et al. IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor . US Patent 6,184,358 dated Feb 6 2001 Qin S, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101: 746-754, 1998. PubMed: 9466968 Loetscher P, et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J. Biol. Chem. 276: 2986-2991, 2001. PubMed: 11110785 Till S, et al. T cell phenotypes of the normal nasal mucosa: induction of Th2 cytokines and CCR3 expression by IL-4. J. Immunol. 166: 2303-2310, 2001. PubMed: 11160286 Jones D, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 96: 685-690, 2000. PubMed: 10887135 |
| 序號(hào) | 文章標(biāo)題 | 操作 |
|---|---|---|
| 1 | ATCC細(xì)胞運(yùn)輸和處理 | 查看詳情 |
| 2 | 其他海外品牌代理 | 查看詳情 |
| 3 | ATCC代理 | 查看詳情 |
| 4 | 購(gòu)買須知 | 查看詳情 |
| 5 | 訂購(gòu)流程 | 查看詳情 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
